Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
Among the CME offerings at the 2025 LUGPA Annual Meeting was a panel discussion titled “Adjuvant PSA [prostate-specific antigen] Biomarkers.” In this video, panelist Jonathan Henderson, MD, a ...
In an interview at the 2025 LUGPA Annual Meeting, Stacy Loeb, MD, shared key takeaways from her session, “Current state of prostate cancer screening.” Loeb is a urologists at NYU Langone Health in New ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...
EG110A targets type C sensory neurons to manage neurogenic detrusor overactivity-related incontinence, preserving other bladder controls. Fast track designation by the FDA allows EG110A to benefit ...
A Lenore Ackerman, MD, discusses a recent guideline amendment that places a greater value on a negative urinalysis in ruling out UTI. The American Urological Association, in collaboration with the ...
Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...
Metabolic health, especially HbA1c levels, significantly influences sexual function in aging men more than age alone. Increases in HbA1c correlate with declines in sperm motility and erectile function ...
The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...
The investigators assessed EFS data from the CREST trial based on subgroups stratified by disease stage. Topline data from the phase 3 CREST trial (NCT04165317) showed that the investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback